Articles tagged ‘heart failure’

Cardiac resynchronisation therapy (CRT) reduces rates of death and re-hospitalisation among heart failure patients according to the European CRT Survey, follow-up results from which were published recently in the European Journal of Heart Failure.¹

The precise populations of patients with chronic heart failure (HF) who could benefit from telemonitoring have been defined by two trials presented recently at the European Society of Cardiology’s (ESC) Heart Failure Congress 2011.

The aldosterone antagonist eplerenone significantly reduces new onset atrial fibrillation and flutter (AFF) in patients with class 2 heart failure, according to a sub-analysis¹ of the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And Survival Study in Heart Failure) trial presented recently at the European Society of Cardiology’s (ESC) Heart Failure Congress 2011.

Atrial fibrillation (AF) and heart failure are two major conditions which commonly co-exist and which are increasing within the ageing populations of developed countries. The challenges of treating these patients to improve outcomes was the topic reviewed by, Professor Dirk van Veldhuisen from University Medical Centre Groningen, The Netherlands, during the Cardiology and Diabetes at the limits 2011 annual scientific symposium, held recently at the University of Cape Town, South Africa.

Patients with heart failure (HF) are twice as likely to die if admitted to general wards than those admitted to cardiology wards, according to a national HF audit published online in Heart.(1)

A new study (1) suggests that persistent dysponea is a robust marker of longer hospitalization and poorer outcomes in patients with acute heart failure.

Atrial Fibrillation, Myocardial Revascularisation and Devices For Heart Failure.

Heart failure patients who used an interactive telehealth system with motivational support tools at home spent less time in hospital and felt their quality of life had significantly improved over 12 months evaluation period, according to the final results of the CARME (CAtalan Remote Management Evaluation) study.

A recently published study finds that heart failure patients willing to take part in clinical trials have a better prognosis than those unwilling to do so.

Symptoms of depression are related to cardiovascular mortality even after adjustment for other prognostic indicators in optimally treated patients with comorbid atrial fibrillation (AF) and congestive heart failure (CHF).